Neurocrine is beefing up its pipeline, splurging $50M on rights to an epilepsy drug

Neurocrine has stepped up with $50 million in cash and a bundle of biobucks to bag rights to an early-stage epilepsy drug out of Xenon Pharmaceuticals.